McKesson and CD&R Sign Definitive Agreement to Acquire Option Care Health for $5.8B
MCK sits 26% above its 52-week low of $723.68.
Summary
McKesson and CD&R signed a definitive agreement to acquire Option Care Health for $32.05 per share, valuing the company at approximately $5.8 billion. McKesson will invest about $1.4 billion for a 49% minority stake. Option Care Health will remain a separate company led by its own management team and will withdraw financial guidance and cancel its Q3 2026 earnings call.
Updated with a Reuters report · What changed
Updates
· Reuters — Option Care Health will remain a separate company led by its own management team and will withdraw financial guidance and cancel its Q3 2026 earnings call.
Key Events · M&A and Partnerships · MCK
-
New · · Reuters
Option Care Health to Remain Separate and Withdraw Guidance
Option Care Health will remain a separate company led by its own management team and will withdraw financial guidance and cancel its Q3 2026 earnings call.
-
Definitive Agreement Signed
McKesson and CD&R signed a definitive agreement to acquire Option Care Health for $32.05 per share, reflecting a total enterprise value of approximately $5.8 billion.
-
McKesson's $1.4B Minority Investment
McKesson will invest approximately $1.4 billion for a 49% minority interest, while CD&R will hold approximately 51% majority ownership.
-
37% Premium to Market
The $32.05 per share price represents a premium of approximately 37% to Option Care Health's closing share price on October 5, 2026.
-
Strategic Expansion into Infusion Services
The acquisition expands McKesson's specialty care capabilities into home and alternate site infusion services, aligning with its strategy to deliver complex therapies in lower-cost community settings.
Analysis · MCK · Trade & Services
A definitive agreement has been signed by McKesson and Clayton Dubilier & Rice to acquire Option Care Health for $32.05 per share, a 37% premium to its October 5 closing price. McKesson will invest approximately $1.4 billion for a 49% minority stake, with CD&R holding the remaining 51%. The deal expands McKesson's specialty care footprint into home and alternate site infusion services, aligning with its strategy to move complex therapies into lower-cost community settings. The transaction is expected to close in the first half of 2027, subject to Option Care Health stockholder approval and regulatory clearances. Option Care Health will remain a separate company led by its own management team and will withdraw financial guidance and cancel its Q3 2026 earnings call.
How filings like this one have moved
In the 30 days to Nov 5, 2026, 43.5% of the 1291 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.16%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MCK was trading at $915.45 on NYSE in the Trade & Services sector, with a market capitalization of approximately $106.7B. The 52-week trading range was $723.68 to $999.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.